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 X-ray Crystallographic and Functional Characterization of BshC: 
The Third Step of Bacillithiol Biosynthesis 
Andrew VanDuinen*, and Paul D. Cook* 
Department of *Cell & Molecular Biology, Grand Valley State University, Allendale, MI 
 
Abstract 
Bacillithiol is a low molecular weight thiol that reduces oxidative stress and regulates thiol 
homeostasis in some Gram-positive bacteria, including the pathogenic Bacillus anthracis and 
Staphylococcus aureus. It has recently been determined that bacillithiol plays a key role in 
resistance to the FDA-approved antibiotic fosfomycin. The biosynthesis of BSH is believed to 
occur via a three step pathway utilizing the enzymes BshA, BshB, and BshC. BshA replaces 
UDP with malate on UDP-N-acetylglucosamine. BshB acts as a deacetylase to produce 
glucosaminyl-malate, and BshC is proposed to add cysteine to glucosaminyl-malate to produce 
bacillithiol. The first solved structure of BshC from Bacillus subtilus contains three key domains 
of interest. The first is the active site which putatively adds a cysteine to glucosaminyl-malate. 
The coiled-coil portion forms a tail-like projection that allows dimerization and is a highly 
conserved region. The third domain of interest contains an ADP molecule. The function of this 
domain is highly uncertain, and the amino acid residues are not highly conserved among BshC 
from various species. PHYRE2 was be used to generate a hypothetical model of BshC from S. 
aureus. The BshC gene was isolated from S. aureus genomic DNA. After expressing and 
isolating the protein, protein crystals will be analyzed via x-ray crystallography to gain insight 
into the different domains of interest. Functional analysis of BshC will also be pursued to clue 
into the mechanism dictating its activity. Understanding how BshC functions will allow specific 
inhibitors to be designed to stop bacillithiol biosynthesis and re-establish fosfomycin as an 
effective antibiotic once again.  
Background and Context 
Bacillithiol  Cells in an oxidative environment can produce free radicals that damage the 
cell. For this reason, low molecular weight thiols form disulfide bonds that protect the cell from 
oxidation.  The major low molecular weight thiols include glutathione (GSH), which is found in 
Gram-negative bacteria, mycothiol (MSH), found in some Gram-positive bacteria, and the 
recently identified bacillithiol (BSH), also found in Gram-positive bacteria.1  Bacillithiol (BSH) 
is classified as a low molecular weight thiol that reduces oxidative stress and regulates thiol 
homeostasis. It is also capable of detoxifying foreign compounds. BSH is present in many  
species of Bacillus including B. anthracis, B. subtilis, B. megaterium, and is also observed 
in Staphylococcus aureus.2 The biosynthesis of BSH is similar to the established pathway of 
MSH.  Using the MSH pathway as a guide, the biosynthesis of BSH was predicted to require 
three enzymes, BshA, BshB, and BshC in the three step biosynthetic pathway shown in 
Scheme1.1 BshA utilizes malate and UDP-N-acetylglucosamine to produce N-
acetylglucosamine-malate. BshB converts this to glucosamine-malate, and BshC putatively acts 
as a cysteinyl ligase to convert glucosamine-malate to bacillithiol.  
 
Scheme 1. Bacillithol biosynthesis pathway.  
BSH and Fosfomycin Fosfomycin tromethamine is effective in treating pathogenic 
Escherichia coli, Citrobacter, Enterobacter, Klebsiella, Serratia, and Enterococcus spp. Taken 
as a three gram oral dose, it effectively treats urinary tract infections caused by the latter 
bacteria.3 Fosfomycin has also been used in combination with other antibiotics to treat the 
biofilm formation of methicillin-resistant Staphylococcus aureus (MRSA).4 Bacillithiol can form 
disulfide bonds between thiols and act as a buffer against alkylating compounds or electrophiles.1 
The FosB enzyme adds BSH to destroy the epoxide ring of fosfomycin conferring resistance to it 
as depicted in Scheme 2.5 Evidence strongly supports BSH as the preferred substrate for this 
phenomenon.6 
 
Scheme 2. Destruction of fosfomycin by FosB utilizing BSH 
When the gene encoding BshA, BshB, or BshC is knocked out, BSH production is eliminated; 
the cell once again becomes sensitive to the antibiotic fosfomycin.7 Because of this, inhibitors to 
any enzyme in the BSH biosynthetic pathway could be designed to re-establish fosfomycin’s 
effectiveness as an antibiotic. 
 MshC Mechanism. The MshC enzyme from the evolutionarily related mycothiol 
biosynthetic pathway acts as an ATP-dependent cysteinyl ligase. The intermediate forms an E-
AMP-cysteine complex. Prior to binding to the enzyme, ATP binds to cysteine creating an 
activated cysteine-AMP complex in the active site which then donates cysteine to glucosaminyl-
malate.8 While BshC has not shown ATP-dependence in in vitro studies and has little overlap of 
amino acid sequence with MshC, the similar Rossmann fold structure of B. subtilus BshC to 
MshC presumably suggests that BshC in fact does function through an activated intermediate 
complex. 
Figure 1. BshC Overall Structure BshC has a core Rossmann fold domain, a coiled-coil tail, 
connecting peptide region one (CP1), and a connecting peptide region two (CP2). 
BshC Structure The overall structure of BshC is depicted in Figure 1. The core 
Rossmann fold (blue) consists of a beta sheet flanked by two alpha helices. Rosmann folds are 
able to bind nucleotides and are found in other cysteine ligases such as MshC. The connecting 
peptide regions flank the core Rossmann fold (green and orange). A unique alpha helical coiled-
coil domain (red) projects out as a tail in the monomeric structure.9  
 
 
Figure 2. ConSurf Analysis of BshC. Dark blue indicates highly conserved amino acid residues 
among species. White area indicates amino acid residues not highly conserved among species. 
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BshC protein from B. subtilis overlaid with top BLAST hits in ConSurf shows areas of 
highly conserved amino acid residues and structure in darker blue and less conserved areas in 
white. The active site domain is highly conserved among species that produce BSH as shown in 
Figure 2A by dark blue in the pocket surrounding citrate and glycerol. The coiled-coil domain of 
BshC, represented as a tail like projection in Figure 2C, also depicts high sequence conservation 
among species. The domain binding ADP in Figure 2B, however, shows a domain not highly 
conserved between species as it is lighter blue and more gray. Based on these observations, it is 
unclear as to whether BshC from other Gram positive species bears amino acid residues that bind 
ADP in a similar manner as B. subtilis BshC does.9  
In order for a drug to be designed that would be able to bind in the active site and inhibit 
BshC activity, more information about the active site amino acid residues and the ADP binding 
pocket is required. A PHYRE2 model was used to establish a hypothetical structure of BshC 
from S. aureus. Protein crystals will be grown to test this hypothetical structure using x-ray 
crystallography to enable characterization of S. aureus BshC. Functional analysis of BshC was 
also executed to understand more about the mechanism of its activity. Expanding understanding 
of the enzyme’s structure and function, and the role of ADP in this, will aid in characterizing 
drugs that inhibit bacillithiol biosynthesis.  
 
Materials and Methods 
Overview  
PHYRE2 was used to predict the structure of S. aureus BshC. To determine the actual structure, 
the BshC gene was first isolated from Staphylococcus aureus genomic DNA. The T7 expression 
system was used to overexpress BshC protein production using IPTG. The S. aureus BshC 
protein was then purified by Ni-NTA affinity chromatography utilizing the his-tag with solubility 
and purity being assessed by SDS-PAGE. Pure protein was used to set up crystallization screens 
and perform functional analysis of BshC.  
 
  
PHYRE2 Structural Alignment 
Protein Homology/Analogy Recognition Engine V 2.0 (PHYRE2) was used to map predict a 
conformational structure of BshC from S. aureus based on the known structure of BshC from B. 
subtilus. 
Isolation of BshC gene from Staphylococcus aureus genomic DNA.  
The BshC gene from S. aureus was isolated from total genomic DNA by designing primers 120 
and 121 that flank the gene and only replicate BshC in a polymerase chain reaction (PCR). The 
designed primers contained NheI and XhoI restriction cut sites on their ends so that the isolated 
gene could be easily manipulated and inserted into the pET-28 expression plasmid. After 
reconstituting the lyophilized primers and genomic DNA, a 50 uL PCR reaction with 0.5 
pmol/uL of each primer and 100 ng of gDNA was carried out with Phusion DNA polymerase 
from NEB. The result was visualized by agarose gel electrophoresis. DNA was isolated from the 
gel band by using the GeneJET PCR Purification Kit and DNA concentration determined to be 
181ng/uL.  
Digestion and Ligation of DNA 
Digestion of the PCR DNA with XhoI and NheI was performed with 3.62 ug of DNA so DNA 
could be ligated into a vector. BshC was ligated into the pET-28 vector using 50 ng of insert and 
50 ng of vector in a 10 uL reaction.  
E. coli Transformation  
About 50 µL of chemically competent Escherichia coli cells of the XL-1blue expression strain 
were incubated on ice with 0.5-4 µL of the BshC pET-28 vector. The mixture rested on ice 10 
minutes and was heat shocked at 42°C for 90 seconds. After resting on ice for 6 minutes, the 
cells were allowed to recover with 250 µL of LB shaking at 200 RPM at 37°C for 1 hour and 
subsequently plated on LB media containing 25 mg/mL of kanamycin and grown overnight at 
37°C.  
  
DNA isolation and Plasmid Digestion 
After picking six individual transformed colonies and growing each of them in 5mL of LB 
overnight, the BshC pET-28 vector was isolated by miniprepping with Thermo Scientific Gene 
JET Plasmid Miniprep Kit. To confirm the BshC gene was successfully inserted into the plasmid 
vector, a digestion with NheI and XhoI restriction enzymes was performed on 7 uL of each 
plasmid and examined by agarose gel electrophoresis. After the BshC gene was shown to be 
ligated in on an agarose gel, the plasmid was sequenced at the University of Michigan DNA 
Sequencing Core facility to ensure it was the actual BshC inserted as expected.  
Plasmid Propagation 
In order to produce more S. aureus BshC plasmid DNA for use, 50 µL of the XL-1Blue 
expression strain of E. coli cells were added to 0.5 µL of 35 ng/µL BshC S. aureus in pET-28. 
After resting on ice for ten minutes, the cells were heat shocked at 42°C for 90 seconds and 
immediately moved to ice for six minutes. Then, 250 µL of LB media was added and the tube 
shaken at 37°C for 45 minutes. After this, the cells were plated onto a 25 mg/mL kanamycin LB 
agar plate and grown overnight at 37°C. An individual colony was picked and placed in a sterile 
culture tube containing 7 mL of LB media and 0.25 µg/mL kanamycin. Four of these tubes were 
shaken at 200 RPM, 37°C overnight. The next day, the cells were pelleted and miniprepped 
using a Thermo Scientific Molecular Biology GeneJET plasmid miniprep kit. The DNA 
concentration and purity were determined via A260 utilizing a Thermo Scientific Nanodrop 
Spectrophotometer. 
Solubility Expression Test 
E. coli was transformed with S. aureus BshC in pET28 according to “E. coli transformation”.  A 
starter culture was used to inoculate 200 mL of LB broth with 25 µg/ml kanamycin and grown 
until the OD600 reached 0.6. Ni-NTA centrifugation chromatography was used to test protein 
expression. A 1.02 g cell pellet was re-suspended in 4 mL lysis buffer. Five cycles of 30 sec. of 
sonication lysed cells and a 100 µL sample of cell lysate was saved. Lysate was centrifuged 10 
min 10,200 RPM at 4˚C and a 100 µL supernatant saved. Then, 1 mL of the supernatant was 
placed in 4 separate 1.5 mL Eppendorf tubes with 200 µL of Ni-NTA resin. The resin was pre-
equilibrated 3 times with 1 mL of lysis solution by centrifuging 2 min at 2,000 RPM 4˚C and 
removing supernatant. The loaded supernatant was centrifuged 2 min at 2,000 RPM 4˚C. 
Supernatant was discarded and 1 mL wash buffer added followed by 2 min centrifugation at 
2000 RPM 4˚C.  The wash step was repeated 3 time until close to negative on a Bradford spot 
test. Then, 100 µL elution buffer was added to the tube and the tube centrifuged 2 min at 10,000 
RPM 4˚C. The supernatant was then saved as eluate. 
Protein Expression 
About 50 µL of chemically competent E. coli cells of the BL-21 expression strain were 
incubated on ice with 0.5-4 µL of pET-28 vector containing BshC S. aureus. The mixture rested 
on ice 10 minutes and was heat shocked at 42°C for 90 seconds. After resting on ice for 6 
minutes, the cells were allowed to recover with 250 µL LB shaking at 200RPM at 37°C for 1 
hour and plated on LB media containing 25 mg/mL of kanamycin and grown overnight at 37°C. 
Cells were grown in 25 µg/mL kanamycin LB media to 0.6 OD600. IPTG was used to induce 
protein expression and the cells incubated at 16˚C overnight with shaking. Cells were harvested 
by centrifugation at 5500 xg for 25 minutes and stored at -80˚C. 
Ni-NTA Affinity Chromatography 
Recombinant E. coli cells with BshC S. aureus protein expressed were re-suspended in lysis 
buffer (20 mM HEPES pH 8, 300 mM NaCl, 10 mM Imidazole). EDTA at 0.5 mM and 0.5 
mg/mL of lysozyme were added to digest the cells. MgCl2 at 5 mM and 5 µg/mL of DNAase 
were added. The reaction was sonicated. Centrifugation at 17,000 xg for 25 minutes, 4°C was 
used to isolate the supernatant which was then loaded onto a Pierce HisPur Ni-NTA column 
equilibrated with lysis buffer. Bradford spot test was used to qualitatively test for the presence of 
any protein in the column eluate. The column was washed until nearly Bradford negative with 
wash buffer (20mM HEPES at pH 8, 300mM NaCl, 25mM Imidazole). Samples were then 
collected, in a single collection vessel, by adding elution buffer (20mM HEPES at pH 8, 300mM 
NaCl, 250mM Imidazole) to the column until nearly Bradford negative. The collected protein 
fractions were dialyzed overnight in dialysis buffer, 20mM HEPES pH 7.5, 50mM NaCl. The 
procedure was repeated for cell pellet of BshC from B. subtilus. 
 
TEV Cleavage  
To remove the hexa-histidine tag from the N-terminus of both BshC B. subtilus and BshC S. 
aureus, his-tagged protein was dialyzed into Ni-NTA lysis buffer after purification. DTT to 0.5 
mM and 1.5 mL of 0.7 mg/mL rTEV in 40% glycerol were added to the sample in dialysis 
tubing. After dialyzing overnight at room temperature, the protein solution was run down a Ni-
NTA column equilibrated with dialysis buffer and collected in fractions. Bradford spot test was 
run on the flow-through and the column was eluted with 250 mM imidazole buffer after testing 
nearly Bradford negative. Bradford was used to qualitatively determine purity and efficiency of 
the TEV cleavage. 
Protein Concentration Determination 
Dialyzed protein was concentrated by centrifugation in Amicon Ultra-15 Centrifugal Filters and 
the concentration checked by using a Cary 60 UV-Vis spectrophotometer. The absorbance at 280 
nm was measured and the extinction coefficient of 55810 used in Beer’s law to determine 
concentration.  Concentrated BshC was frozen in liquid nitrogen and stored at -80°C. 
SDS-PAGE 
10% SDS-PAGE gels were made by using Amresco instructions and poured 0.75mm thin. 
Samples of 40 µL from the solubility expression test were prepared for electrophoresis by 
boiling for five minutes with 2X SDS-PAGE buffer (100 mM tris-HCL pH 6.8, 2%SDS, 4% β-
mercaptoethanol, 15% glycerol, 0.2 mg/mL bromothymol blue) in a 1:1 ratio. Electrophoresis 
was run at 190 V, stained with Coomaissie brilliant blue, and destained with 10% MeOH and 
10% AcOH in water. Purity was qualitatively assessed. 
Crystallization Screens 
Crystallization screens were set using the vapor diffusion hanging drop method with Hampton 
Research Crystal Screen I and II as well as PEG Ion I and II. 400 µL of a condition was placed in 
each well. A 12 mg/mL, 2 µL drop of BshC from S. aureus was pippeted on a cover slip and 2 
µL of well solution added to the drop. The slip was inverted over the well with mineral oil 
forming an air tight seal. Two drops were set up on each cover slip with either 5 mM AMP or 
apo enzyme. Crystallization screens were also performed on his-tag cleaved BshC S. aureus in 
5mM cysteine, 2mM BSH with 2mM DTT, or apo conditions. 
Functional Analysis of BshC. 
To qualitatively analyze BshC activity, Bacillus subtilus BshC was added to a BshC substrate 
reaction containing. The substrate reaction contained 1mM UDP-glcNAc, 1 mM malate, 10 ug 
BshA, and 10ug of BshB. After reacting for 2 hours at 37°C, 2 mM of cysteine and 5 uL of  2 
mg/mL BshC were added to 200 uL assays. To each reaction tube 0.5 mM GTP, 0.5 mM CTP, 
0.5 mM ATP, 0.5 mM serine with 0.5 mM ATP, no cysteine with 0.5 mM ATP, 100 uM zinc 
with 0.5 mM ATP, or 0.5 mM NADH was added. These assay tubes were reacted at 37°C for 30 
minutes. Chloroform extraction was performed and the upper aqueous layer saved for HPLC by 
storing at -20°C. The process was repeated with S. aureus BshC with 0.5 mM ATP. 
  
Results and Discussion 
A         B  
 
 
 
 
 
 
 
Figure 3. BshC B. subtilus ADP Binding Site Compared to PHYRE2 Model of BshC S. aureus. (A.) 
Ribbon structure of B. subtilus (green) and model of S. aureus (blue) showing extra amino acids in side 
loop. (B.) Superposition of the ADP binding site in B. subtilus structure (green) and S. aureus model 
(magenta). 
The PHYRE2 modeling server was used to generate a hypothetical model to predict interactions 
in the BshC structure from S. aureus, specifically in the ADP binding site. The model reported a 
confidence of 100%. Figure 3A shows a ribbon model of the predicted S. aureus model 
superimposed on the actual B. subtilus structure. Two extra amino acids are present in the S. 
aureus protein sequence which results in a larger loop over the ADP binding pocket. Figure 3B 
depicts superposition of the ADP binding site in B. subtilus (green) and S. aureus (magenta).  
Figure 4. Multiple sequence alignment of ADP binding pocket residues. The residues of the ADP 
binding pocket in B. subtilis BshC are shown aligned with the BshC sequences of other Firmicutes. 
Residues from the B. subtilis structure that make hydrogen bonding or π-stacking interactions with ADP 
are indicated with a pound sign (#). 
When the amino acid sequences of a few Bacillus species are aligned in Figure 4, it is found that 
residues that interact with ADP are conserved. However, when the sequences of some 
Staphylococcus species are aligned with the Bacillus species, they do not contain conserved 
residues at the positions that interact with ADP (Figure 4). In Figure 3B, the binding pocket in B. 
subtilus exhibits π-stacking interactions from W506 and Y510. The PHYRE2 model predicts 
ADP interactions with the amino acid residues in BshC S. aureus. The S. aureus ADP binding 
pocket is predicted to be dissimilar with Q509 present instead of Y510. The Q509 is not able to 
facilitate π-stacking interactions like Y510 which suggests ADP may not bind as well, if at all. 
Taken together, this information supports a hypothesis that BshC S. aureus might not have an 
ADP binding site. Nevertheless, PHYRE2 only predicts the location of amino acid residues and 
not their exact conformation. A crystal structure is necessary to determine the actual location of 
the amino acid residues and how they interact with ADP. 
 
Figure 5. Agarose gel of PCR from S. aureus genomic DNA. BshC was amplified by PCR from S. 
aureus genomic DNA. Lane one contains a DNA ladder. Lane 2 contains PCR reaction of BshC gene 
from S. aureus genomic DNA. 
PCR product amplified from S. aureus genomic DNA was analyzed by agarose gel 
electrophoresis. The molecular weight DNA ladder in lane one establishes standard MW to 
determine fragment size. Using the MW ladder in lane one of Figure 5, the BshC gene product in 
lane two was estimated to be about 1600 bp. This corresponds to the actual BshC gene size 
suggesting PCR was successful. The small bands in lane two are most likely the 50 bp primers –
they just do not resolve well on the 1.5% agarose gel. The PCR product was subsequently 
recovered from the gel slice and ligated into the pET-28 vector. E. coli cells were successfully 
transformed with ligation reaction and plated on LB kanamycin plates to select for transformed 
cells. Because of this, six different colonies were selected and grown overnight in LB kanamycin 
and the cells miniprepped to isolate the pET-28 BshC vector. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Agarose gel of Plasmid Digestion. Lane one contains DNA ladder. Lane two contains negative 
control. Lanes three through eight contain the digestion reactions of potential pET28 with BshC insert. 
To determine if ligation of BshC into the pET-28 vector was successful, the plasmid DNA form 
miniprepped cells was digested with XhoI and NheI restriction enzymes. The result, portrayed in 
Figure 6, was that only the sample in lane five has BshC successfully ligated into pET-28. The 
larger band in lane five is the pET-28 vector and the smaller one the gene insert. 
The only successful BshC pET-28 vector was sent in for DNA sequencing to confirm the identity 
of the DNA insert. Figure 7 displays the sequenced DNA aligned with the known sequence of 
BshC S. aureus. The sequence alignment is almost identical, which is expected, except for a few 
nucleotides near the end of the forward primer because sequencing gets less accurate after 900 
bp. The reverse primer accurately overlaps those bases. The alignment confirms the BshC gene 
was successfully inserted into pET-28. The chromatograms from both the forward and reverse 
DNA sequencing reactions have been included in the appendix for reference. 
CLUSTAL 2.1 multiple sequence alignment 
BshCFwd         CGTGGGAATTCCCTCTGAATATTTTGTTTACTTTAAGAAGGAGATATACCATGGGCAGCA 60 
BshCaureus      ------------------------------------------------------------                                                                         
BshCFwd         GCCATCCCTCNTCATCATCACAGCAGCGAGAACCTGTACTTCCAGGGCCATATGGCTAGC 120 
BshCaureus      ------------------------------------------------------------                                                                            
BshCFwd         ATGGACTGTAAAGTAGTTAGTTTAAATGAAAAAGATCAGTTTATACCAAAAATAAAGAGC 180 
BshCaureus      ATGGACTGTAAAGTAGTTAGTTTAAATGAAAAAGATCAGTTTATACCAAAAATAAAGAGC 60 
                ************************************************************ 
BshCFwd         AGTGACCCTGTAATAACAGGATTATTTCAATATGATGCAGCTCAACAAACTAGTTTTGAA 240 
BshCaureus      AGTGACCCTGTAATAACAGGATTATTTCAATATGATGCAGCTCAACAAACTAGTTTTGAA 120 
                ************************************************************ 
BshCFwd         AAAAGGATGTCTAAAGAAAATAATGGAAGAGAAGCGGCATTAGCGAATGTTATTCGTGAA 300 
BshCaureus      AAAAGGATGTCTAAAGAAAATAATGGAAGAGAAGCGGCATTAGCGAATGTTATTCGTGAA 180 
                ************************************************************ 
BshCFwd         TATATGAGTGATTTAAAGCTTTCAAGTGAACAAGAATTAAACATACAACATTTAGCTAAT 360 
BshCaureus      TATATGAGTGATTTAAAGCTTTCAAGTGAACAAGAATTAAACATACAACATTTAGCTAAT 240 
                ************************************************************ 
BshCFwd         GGTTCAAAAGTTGTGATTGGTGGACAACAAGCAGGGCTTTTCGGGGGACCATTGTATACA 420 
BshCaureus      GGTTCAAAAGTTGTGATTGGTGGACAACAAGCAGGGCTTTTCGGGGGACCATTGTATACA 300 
                ************************************************************ 
BshCFwd         TTCCATAAAATATTTTCAATCATTACTTTATCTAAGGAATTAACGGATACACATAAGCAA 480 
BshCaureus      TTCCATAAAATATTTTCAATCATTACTTTATCTAAGGAATTAACGGATACACATAAGCAA 360 
                ************************************************************ 
BshCFwd         CAAGTAGTACCAGTTTTTTGGATTGCAGGAGAAGATCATGATTTCGATGAAGTGAATCAT 540 
BshCaureus      CAAGTAGTACCAGTTTTTTGGATTGCAGGAGAAGATCATGATTTCGATGAAGTGAATCAT 420 
                ************************************************************ 
BshCFwd         ACATTTGTTTATAACGAAAATCATGGGTCGCTGCATAAGGTTAAATATCATACAATGGAG 600 
BshCaureus      ACATTTGTTTATAACGAAAATCATGGGTCGCTGCATAAGGTTAAATATCATACAATGGAG 480 
                ************************************************************ 
BshCFwd         ATGCCAGAGACGACTGTCTCTAGATATTATCCTGATAAGGCTGAGTTGAAACAAACTTTA 660 
BshCaureus      ATGCCAGAGACGACTGTCTCTAGATATTATCCTGATAAGGCTGAGTTGAAACAAACTTTA 540 
                ************************************************************ 
BshCFwd         AAAACGATGTTCATTCATATGAAAGAAACTGTTCATACACAAGGTCTACTGGAGATTTGT 720 
BshCaureus      AAAACGATGTTCATTCATATGAAAGAAACTGTTCATACACAAGGTCTACTGGAGATTTGT 600 
                ************************************************************ 
BshCFwd         GACAGAATTATTGACCAATATGACTCGTGGACTGATATGTTTAAAGCACTACTGCATGAA 780 
BshCaureus      GACAGAATTATTGACCAATATGACTCGTGGACTGATATGTTTAAAGCACTACTGCATGAA 660 
                ************************************************************ 
BshCFwd         ACATTTAAAGCATATGGCGTTCTATTTATAGATGCGCAGTTTGAGCCGTTAAGAAAAATG 840 
BshCaureus      ACATTTAAAGCATATGGCGTTCTATTTATAGATGCGCAGTTTGAGCCGTTAAGAAAAATG 720 
                ************************************************************ 
BshCFwd         GAAGCGCCTATGTTTAAAAAGATTTTGAAAAAACATCAGTTGCTTGATGATGCTTTTAGA 900 
BshCaureus      GAAGCGCCTATGTTTAAAAAGATTTTGAAAAAACATCAGTTGCTTGATGATGCTTTTAGA 780 
                ************************************************************ 
BshCFwd         GCAACACANCAACGTACTCAAAATCAAGGCTTGAATGCGATGATACAAACAGATACAAAT 960 
BshCaureus      GCAACACAACAACGTACTCAAAATCAAGGCTTGAATGCGATGATACAAACAGATACAAAT 840 
                ******** *************************************************** 
BshCFwd         GTTCATTTATTCTTTACATGATGAAAATATGCGTCAATTAGTTTCGTATGATGGTANGCN 1020 
BshCaureus      GTTCATTTATTCTT-ACATGATGAAAATATGCGTCAATTAGTTTCGTATGATGGTAAGCA 899 
                ************** ***************************************** **  
BshCFwd         TTTTAAATTAAATAAACCGGATA------------------------------------- 1043 
BshCaureus      TTTTAAATTAAATAAAACAGATAAGACATATATAAAGGAAGAAATTATAAATATTGCGGA 959 
                **************** * ****                                      
BshCFwd         --------------------------------------GACCTTN--------------- 1050 
BshCaureus      AAATCAACCTGAATTATTTTCTAATAATGTAGTGACAAGACCATTAATGGAAGAATGGTT 1019 
                                                      **** *                 
BshCFwd         ------------------------------------------------------------ 
BshCaureus      ATTTAACACGGTGGCATTTGTTGGAGGACCGAGTGAAATTAAGTACTGGGCTGAACTAAA 1079 
BshCFwd         ------------------------------------------------------------ 
BshCaureus      AGATGTATTTGAACTATTTGATGTTGAAATGCCTATCGTGATGCCAAGGCTTAGAATTAC 1139 
 
CLUSTAL 2.1 multiple sequence alignment 
 BshCaureus      AAAACGATGTTCATTCATATGAAAGAAACTGTTCATACACAAGGTCTACTGGAGATTTGT  
BshCRev         --------------CCAATATGACTCGNGGACTGATATGTTTAAAGCNCTACTGCNTGAA 46 
BshCaureus      GACAGAATTATTGACCAATATGACTCGTGGACTGATATGTTTAAAGCACTACTGCATGAA 660 
                              ************* ******************* ******* **** 
BshCRev         ACCATTTAAAGCATATGGCGTTCTATTTATAGATGCGCAGTTTGAGCCGTTAAGAAAAAT 106 
BshCaureus      AC-ATTTAAAGCATATGGCGTTCTATTTATAGATGCGCAGTTTGAGCCGTTAAGAAAAAT 719 
                ** ********************************************************* 
BshCRev         GGAAGCGCCTATGTTTAAAAAGATTTTGAAAAAACATCAGTTGCTTGATGATGCTTT-AG 165 
BshCaureus      GGAAGCGCCTATGTTTAAAAAGATTTTGAAAAAACATCAGTTGCTTGATGATGCTTTTAG 779 
                ********************************************************* ** 
BshCRev         AGCAACACAACAACGTACTCAAAATCAAGGCTTGAATGCGATGATACAAACAGATACAAA 225 
BshCaureus      AGCAACACAACAACGTACTCAAAATCAAGGCTTGAATGCGATGATACAAACAGATACAAA 839 
                ************************************************************ 
BshCRev         TGTTCATTTATTCTTACATGATGAAAATATGCGTCAATTAGTTTCGTATGATGGTAAGCA 285 
BshCaureus      TGTTCATTTATTCTTACATGATGAAAATATGCGTCAATTAGTTTCGTATGATGGTAAGCA 899 
                ************************************************************ 
BshCRev         TTTTAAATTAAATAAAACAGATAAGACATATATAAAGGAAGAAATTATAAATATTGCGGA 345 
BshCaureus      TTTTAAATTAAATAAAACAGATAAGACATATATAAAGGAAGAAATTATAAATATTGCGGA 959 
                ************************************************************ 
BshCRev         AAATCAACCTGAATTATTTTCTAATAATGTAGTGACAAGACCATTAATGGAAGAATGGTT 405 
BshCaureus      AAATCAACCTGAATTATTTTCTAATAATGTAGTGACAAGACCATTAATGGAAGAATGGTT 1019 
                ************************************************************ 
BshCRev         ATTTAACACGGTGGCATTTGTTGGAGGACCGAGTGAAATTAAGTACTGGGCTGAACTAAA 465 
BshCaureus      ATTTAACACGGTGGCATTTGTTGGAGGACCGAGTGAAATTAAGTACTGGGCTGAACTAAA 1079 
                ************************************************************ 
BshCRev         AGATGTATTTGAACTATTTGATGTTGAAATGCCTATCGTGATGCCAAGGCTTAGAATTAC 525 
BshCaureus      AGATGTATTTGAACTATTTGATGTTGAAATGCCTATCGTGATGCCAAGGCTTAGAATTAC 1139 
                ************************************************************ 
BshCRev         TTATTTAAATGACCGTATAGAAAAATTACTTTCGAAATACAATATTCCATTAGAAAAAGT 585 
BshCaureus      TTATTTAAATGACCGTATAGAAAAATTACTTTCGAAATACAATATTCCATTAGAAAAAGT 1199 
                ************************************************************ 
BshCRev         GTTAGTCGATGGTGTTGAAGGAGAAAGAAGTAAGTTTATTAGAGAACAAGCATCACATCA 645 
BshCaureus      GTTAGTCGATGGTGTTGAAGGAGAAAGAAGTAAGTTTATTAGAGAACAAGCATCACATCA 1259 
                ************************************************************ 
BshCRev         ATTTATTGAAAAGGTAGAAGGTATGATTGAACAACAGCGTCGTCTAAACAAAGACTTATT 705 
BshCaureus      ATTTATTGAAAAGGTAGAAGGTATGATTGAACAACAGCGTCGTCTAAACAAAGACTTATT 1319 
                ************************************************************ 
BshCRev         AGATGAAGTGGCGGGGAATCAAAATAATATTAACCTTGTGAATAAAAATAATGAAATTCA 765 
BshCaureus      AGATGAAGTGGCGGGGAATCAAAATAATATTAACCTTGTGAATAAAAATAATGAAATTCA 1379 
                ************************************************************ 
BshCRev         TATACAACAGTATGATTATTTGTTAAAACGTTATCTTTTAAACATTGAAAGAGAAAACGA 825 
BshCaureus      TATACAACAGTATGATTATTTGTTAAAACGTTATCTTTTAAACATTGAAAGAGAAAACGA 1439 
                ************************************************************ 
BshCRev         CATCAGTATGAAGCAATTTAGAGAAATTCAAGAAACACTCCATCCAATGGGAGGATTACA 885 
BshCaureus      CATCAGTATGAAGCAATTTAGAGAAATTCAAGAAACACTCCATCCAATGGGAGGATTACA 1499 
                ************************************************************ 
BshCRev         AGAAAGAATATGGAATCCACTTCAAATTTTGAATGATTTTGGGACAGATGTGTTCAAGCC 945 
BshCaureus      AGAAAGAATATGGAATCCACTTCAAATTTTGAATGATTTTGGGACAGATGTGTTCAAGCC 1559 
                ************************************************************ 
BshCRev         CTCCACCTATCCACCACTTTCTTACACTTTTGATCATATTATTATAAAACCTTAACTCGA 1005 
BshCaureus      CTCCACCTATCCACCACTTTCTTACACTTTTGATCATATTATTATAAAACCTTAA----- 1614 
                *******************************************************      
BshCRev         GCACCACCACCACCACCACTGAGATCCGGCTGCTACAAGCCCGAAGGAGNAG 1057 
BshCaureus      ---------------------------------------------------- 
   Consensus key: * :single, fully conserved residue    - : no consensus 
Figure 7. Sequence Alignment of BshC S. aureus. Sequence of the PCR product was aligned to the 
known WT sequence of S. aureus BshC using ClustalW for both the sequence from the T7 forward 
primer and the complement of the sequence from the reverse primer. 
 Figure 8. BshC Solubility Expression SDS-PAGE. SDS-PAGE on small scale protein expression of 
BshC S. aureus, and subsequent large scale, was used to assess expression, solubility, and purity. 
Expression and purity of BshC protein was tested on a small scale and analyzed by SDS-PAGE 
in Figure 8. The ladder is very faint in lanes 1 and 2 but MW bands are still legible. Lanes 5 and 
6 show soluble proteins in the lysate and supernatant. Both of these lanes have many bands, 
evidence of many different proteins present. Lane 7, however, only contains one band at 62kDa 
which is the estimated MW of BshC S. aureus. BshC protein was successfully purified as 
evidenced by the single band in lane 7. Lane 3 shows the result of affinity chromatography on a 
large scale. It can be concluded that the protein is pure because there is such a strong signal of 
BshC present when compared to the potential contaminating bands. Too much concentrated 
protein was loaded and next time loading less volume would give a more accurate assessment of 
purity. rTEV was successfully used to cleave the his-tag from the protein as determined 
qualitatively by Bradford assay. 
Despite a multitude of crystallization screens, no BshC S. aureus protein crystals have yet been 
grown. At this point, no actual x-ray crystallographic data was able to be collected. Therefore, 
the model predicted by PHYRE2 is currently the best model available. The idea that BshC from 
S. aureus may not bind ADP is currently being tested by obtaining a crystal structure which 
accurately reflects protein structure. In vitro assays of BshC B. subtilis were analyzed by HPLC 
analysis with substrates cysteine, glucosaminyl-malate, and either ATP, CTP, GTP, NADH, Zn2+ 
with ATP, or serine with ATP.  Assays were also performed on BshC S. aureus with cysteine, 
glucosaminyl-malate, and ATP. The results did not reveal any enzyme activity. The HPLC trace 
for BshC with NADH had an unidentifiable peak detected at 4.681 minutes. Future work is 
needed to characterize this finding. Employing x-ray crystallography to understand how the 
structure of BshC dictates its function will allow specific inhibitors to be designed that stop 
bacillithiol biosynthesis. The absence of bacillithiol will allow fosfomycin to be re-established as 
an effective antibiotic once again. 
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Appendix
Supplemental Figure 1. Chromatogram from Forward Primer. Chromatogram produced by DNA 
sequencing PCR product with the T7 forward primer. 
 
Supplemental Figure 2. Chromatogram from Reverse Primer. Chromatogram produced by DNA 
sequencing PCR product for the reverse primer.  
